Celmatix was a next-generation women’s health company dedicated to transforming reproductive healthcare through data-driven, personalized medicine. By leveraging big data, genomics, and artificial intelligence, Celmatix developed innovative products aimed at improving fertility outcomes and overall women's health. Key contributions included the Fertilome® genetic test and a proprietary data platform designed to provide deeper insights into female reproductive biology. In June 2022, Celmatix's key assets, including its preclinical-stage MAGE-A9 program, Fertilome® test, and digital platform, were acquired by Organon, a global women's health company, to further accelerate innovation in the field.
The New York headquarters served as the core for Celmatix's operations, including research and development, data science, product innovation, and corporate strategy, driving its mission in advancing women's reproductive health.
Celmatix's office was situated in a modern commercial building in Manhattan's Financial District, offering a dynamic environment and access to collaborative workspaces. Specific internal architectural details were proprietary to their leased space.
Celmatix cultivated a mission-driven, innovative, and collaborative work environment. The team was characterized by a passion for applying cutting-edge science and technology to solve complex challenges in women's health, emphasizing data-informed decisions and scientific excellence.
The New York City headquarters was pivotal for Celmatix, providing access to a rich talent pool in technology, data science, and medicine, and facilitating connections with research institutions, partners, and the investment community vital for a growing biotech firm.
While Celmatix was headquartered in the United States, its research, data-driven insights, and products, particularly in the realm of fertility and genomics, held global relevance and application. The company engaged in collaborations that extended its reach, and its technologies were designed with potential for international impact. Following the acquisition of its assets by Organon, Celmatix's innovations are now part of a company with an extensive global operational footprint, potentially broadening their availability worldwide.
222 Broadway, 19th Floor
New York
NY
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Celmatix Therapeutics' leadership includes:
Celmatix Therapeutics has been backed by several prominent investors over the years, including:
In the 12 months preceding its asset acquisition by Organon in June 2022, the most significant 'executive news' for Celmatix centered on this major transition. This event fundamentally reshaped the company, leading to the wind-down of Celmatix as an independent operational entity. Consequently, its leadership structure was dissolved, with assets and technology integrated into Organon. Publicly announced individual executive hires or departures at Celmatix, distinct from the acquisition context, were not prominent during this specific period.
Discover the tools Celmatix Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
During its operational period, Celmatix likely used standard corporate email formats, commonly based on employee names such as [first].[last]@[companyname].com. Following the asset acquisition by Organon, active communication pertaining to former Celmatix technologies would now use Organon's email systems. The @celmatix.com domain is likely no longer actively used for new communications.
[first].[last]@celmatix.com
Format
jane.doe@celmatix.com
Example
85%
Success rate
Organon News • June 22, 2022
Organon announced the completion of its acquisition of assets from Celmatix, Inc. This strategic move included Celmatix's preclinical-stage MAGE-A9 program for ovarian cancer, its innovative Fertilome® genetic test, and the Celmatix digital health platform, aiming to bolster Organon's portfolio in women's health....more
PRNewswire • February 5, 2019
Celmatix and CooperSurgical unveiled a partnership to broaden access to MyFertilityCompass, a digital tool designed to offer women personalized, data-driven insights into their fertility. Powered by Celmatix's extensive research, the tool aimed to help women make proactive decisions regarding their reproductive health....more
MobiHealthNews • March 14, 2017
Celmatix announced the commercial launch of Fertilome®, a pioneering genetic test. It was designed to screen for dozens of genetic markers associated with female fertility, providing women and their healthcare providers with personalized information to better understand reproductive health risks and inform family planning strategies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Celmatix Therapeutics, are just a search away.